intralesional ranibizumab

Phase 1Monoclonal antibody

UUniversiti Sains Malaysia

intralesional ranibizumab is one of 16 biologic programs targeting Pterygium. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PterygiumActive, not recruiting

PterygiumPhase 1

Active, not recruiting

Competition

Competitive Landscape

36 competitors in Pterygium

#DrugCompanyPhaseTrials

Pred Forte

Novartis

Approved

1 2

Trexall

Alnylam Pharmaceuticals

Approved

1 3

Mitosol

Cellcept

1 5

Avastin

BBio-Thera Solutions

Phase 3

8 6

Tripterygium Wilfordii

ZZhi-Hong Liu, M.D.

Approved

1 7

Lucentis

Roche

Phase 2

1 8

Yisaipu

SSun Yat-sen University

Approved

1 9

Persantine

Boehringer Ingelheim

Phase 2

1 10

PRO-155

LLaboratorios Sophia S.A de C.V.

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pterygium1 trial

Effects of Ranibizumab in Primary Pterygium Surgery

Completed·UUniversiti Sains Malaysia·Phase 1·NCT04878835·52 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for intralesional ranibizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — intralesional ranibizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for intralesional ranibizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Universiti Sains Malaysia company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: UUniversiti Sains Malaysia

intralesional ranibizumab

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pterygium1 trial

References

Drug Info

Quick Facts

Related News